Leerink Partners Starts Rhythm Pharmaceuticals (RYTM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
July 9, 2025 4:18 PM EDTLeerink Partners analyst Faisal Khurshid raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $102.00 (from $88.00) while maintaining a Outperform rating.
The analyst comments "We are updating our estimates for RYTM following this morning's disclosure of bivamelagon Ph 2 data in acquired... More



